Contact FutureLearn for Support
Skip main navigation
We use cookies to give you a better experience, if that’s ok you can close this message and carry on browsing. For more info read our cookies policy.
We use cookies to give you a better experience. Carry on browsing if you're happy with this, or read our cookies policy for more information.
EGFR and lung cancer

EGFR and tumor cells


Binding of EGFR to its cognate ligands leads to autophosphorylation of the receptor itself by the tyrosine kinase activity.

A variety of signal transduction pathways are subsequently activated, which are involved in regulating cellular proliferation, differentiation, and survival.

Although EGFR is also produced in normal cells, it is overexpressed in a variety of tumor cell lines and has been associated with poor prognosis and reduced survival rate.

Moreover, EGFR activation in tumor cells also plays a role in resistance to chemotherapy and radiation treatment.

Over the past two decades, much effort has been directed at developing anticancer agents which can interfere with EGFR activity.

Now, the most common pharmacologic approaches to EGFR inhibition have been achieved by the developments of monoclonal antibodies and small-molecule inhibitors.

Share this article:

This article is from the free online course:

Introduction to Translational Research: Connecting Scientists and Medical Doctors

Taipei Medical University

Course highlights Get a taste of this course before you join: